Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYMR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKymera COO Jeremy Chadwick resigns, will stay on as advisor through November
Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
medium
Chief Operating Officer Jeremy Chadwick resigned effective June 5, 2026, but will remain with the company as an advisor through November 2026, providing continuity during the leadership transition.
Item 5.02 verify on EDGAR → -
low
The company disclosed the resignation was for personal reasons and not due to any disagreement with company practices or policies, indicating an amicable departure.
Item 5.02 verify on EDGAR →
Summary
Kymera Therapeutics announced the resignation of Chief Operating Officer Jeremy Chadwick, effective June 5, 2026. While executive departures can signal operational challenges, the company emphasized this was a personal decision unrelated to business disagreements. Chadwick will remain as an advisor through November, suggesting an orderly transition rather than an abrupt exit.
For retail investors, the key question is whether Kymera can maintain operational momentum during this transition. The COO role is critical for executing clinical trials and scaling operations at biotech companies. Watch for the company's next quarterly earnings call or investor update for details on succession planning and whether operational timelines remain on track. The advisory period through November suggests management is working to minimize disruption.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify